CRA was retained by the claimant in an arbitration dispute concerning the alleged breach of a non-compete clause in an agreement to distribute a prescription women’s health product in a country in Asia. A CRA life sciences expert provided an expert report regarding the quantum of lost profits suffered by the claimant because of the alleged breach. In computing the estimate of quantum, the CRA Life Sciences team analyzed and addressed questions regarding the timing of market entry and product sales absent the alleged breach as well as the incremental profit per unit sold.
2024 International Arbitration review: Updates and trends
Dear Clients and Friends, Our activities in 2024 reflected ongoing trends from 2023 and emerging forces affecting the landscape for investors and companies...